Cita APA

Ribera, J., Prawitz, T., Freitag, A., Sharma, A., Dobi, B., Rizzo, F., . . . Patos, P. (2023). Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Citación estilo Chicago

Ribera, Jose-Maria|||0000-0003-1042-6024, Thibaud Prawitz, Andreas Freitag, Anuj Sharma, Balázs Dobi, Federica|||0000-0002-5945-8222 Rizzo, Lorenzo Sabatelli, y Petros Patos. Ponatinib Vs. Imatinib As Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. 2023.

Cita MLA

Ribera, Jose-Maria|||0000-0003-1042-6024, et al. Ponatinib Vs. Imatinib As Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. 2023.